Actualités ProMIS Neurosciences Inc - PMN | Actions Toronto Stock Exchange

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

Premium

ProMIS Neurosciences Announces Second Quarter 2024 Financial Results and Recent Highlights

Reported positive topline data from first-in-human Phase 1a clinical trial of PMN310 as a treatment for...

ProMIS Neurosciences Announces Data on the Pathogenic Role of Toxic Misfolded SOD1 Aggregates in ALS Published in Acta Neuropathologica and Open Biology

Body of work supports targeting misfolded proteins as a therapeutic strategy for ALS with the potential to...

ProMIS Neurosciences to Participate in BTIG Virtual Biotechnology Conference 2024

CAMBRIDGE, Massachusetts and TORONTO, Ontario, Aug. 01, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc...

ProMIS Neurosciences Showcases Novel Vaccine Approach for Maximal Targeting of Toxic Amyloid-Beta Oligomers at the 2024 Alzheimer’s Association International Conference

Preclinical data showed strong antibody responses with no measurable pro-inflammatory T cell responses against...

ProMIS Neurosciences Reports Positive Top-Line Data from its Phase 1a Alzheimer's Trial

Topline results demonstrated a favorable safety profile and tolerability across four ascending dose levels in...

ProMIS Neurosciences Announces Up to $122.7 Million Private Placement Financing

$30.3 million financing upfront with up to an additional $92.4 million tied to exercise of warrants, with...

ProMIS Neurosciences Announces First Quarter 2024 Financial Results and Recent Highlights

CAMBRIDGE, Massachusetts and TORONTO, Ontario, May 14, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc...

ProMIS Neurosciences Publishes Study Highlighting Oligomer Selectivity and Benefit of Amyloid-Beta-Directed Antibodies

CAMBRIDGE, Massachusetts and TORONTO, Ontario, April 30, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc...

ProMIS Neurosciences Publishes in the Journal of Biological Chemistry on the Interaction Between Pathogenic Proteins as a Treatment Target for ALS

CAMBRIDGE, Massachusetts and TORONTO, Ontario, April 09, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences...

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

ProMIS Neurosciences Inc (PMN)

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

PMN Actualités

ProMIS Neurosciences Announces Second Quarter 2024 Financial Results and Recent Highlights

ProMIS Neurosciences Announces Data on the Pathogenic Role of Toxic Misfolded SOD1 Aggregates in ALS Published in Acta Neuropathologica and Open Biology

ProMIS Neurosciences to Participate in BTIG Virtual Biotechnology Conference 2024

ProMIS Neurosciences Showcases Novel Vaccine Approach for Maximal Targeting of Toxic Amyloid-Beta Oligomers at the 2024 Alzheimer’s Association International Conference

ProMIS Neurosciences Reports Positive Top-Line Data from its Phase 1a Alzheimer's Trial

ProMIS Neurosciences Announces Up to $122.7 Million Private Placement Financing

ProMIS Neurosciences Announces First Quarter 2024 Financial Results and Recent Highlights

ProMIS Neurosciences Publishes Study Highlighting Oligomer Selectivity and Benefit of Amyloid-Beta-Directed Antibodies

ProMIS Neurosciences Publishes in the Journal of Biological Chemistry on the Interaction Between Pathogenic Proteins as a Treatment Target for ALS

ProMIS Neurosciences to Present in Upcoming Investor Conferences in April

ProMIS Neurosciences Announces Full Year 2023 Financial Results and Recent Highlights

ProMIS Neurosciences Strengthens Global Intellectual Property Portfolio

ProMIS Neurosciences to Present at the 2024 BIO CEO & Investor Conference

ProMIS Neurosciences Achieves Milestone in Development of Therapeutic Alpha-Synuclein Vaccine

ProMIS Neurosciences Issues Letter to Shareholders

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

ProMIS Neurosciences Inc (PMN) Actualités

ProMIS Neurosciences Inc (PMN)

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

PMN Actualités

ProMIS Neurosciences Announces Second Quarter 2024 Financial Results and Recent Highlights

ProMIS Neurosciences Announces Data on the Pathogenic Role of Toxic Misfolded SOD1 Aggregates in ALS Published in Acta Neuropathologica and Open Biology

ProMIS Neurosciences to Participate in BTIG Virtual Biotechnology Conference 2024

ProMIS Neurosciences Showcases Novel Vaccine Approach for Maximal Targeting of Toxic Amyloid-Beta Oligomers at the 2024 Alzheimer’s Association International Conference

ProMIS Neurosciences Reports Positive Top-Line Data from its Phase 1a Alzheimer's Trial

ProMIS Neurosciences Announces Up to $122.7 Million Private Placement Financing

ProMIS Neurosciences Announces First Quarter 2024 Financial Results and Recent Highlights

ProMIS Neurosciences Publishes Study Highlighting Oligomer Selectivity and Benefit of Amyloid-Beta-Directed Antibodies

ProMIS Neurosciences Publishes in the Journal of Biological Chemistry on the Interaction Between Pathogenic Proteins as a Treatment Target for ALS

ProMIS Neurosciences to Present in Upcoming Investor Conferences in April

ProMIS Neurosciences Announces Full Year 2023 Financial Results and Recent Highlights

ProMIS Neurosciences Strengthens Global Intellectual Property Portfolio

ProMIS Neurosciences to Present at the 2024 BIO CEO & Investor Conference

ProMIS Neurosciences Achieves Milestone in Development of Therapeutic Alpha-Synuclein Vaccine

ProMIS Neurosciences Issues Letter to Shareholders

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application